Table of Contents Author Guidelines Submit a Manuscript
Corrigendum

A corrigendum for this article has been published. To view the corrigendum, please click here.

BioMed Research International
Volume 2014 (2014), Article ID 103718, 9 pages
http://dx.doi.org/10.1155/2014/103718
Clinical Study

Value of Fused 18F-Choline-PET/MRI to Evaluate Prostate Cancer Relapse in Patients Showing Biochemical Recurrence after EBRT: Preliminary Results

1Nuclear Medicine Department, E.O. Galliera Hospital, Mura delle Cappuccine 14, 16128 Genoa, Italy
2Radiology Department, E.O. Galliera Hospital, Mura delle Cappuccine 14, 16128 Genoa, Italy
3Radiotherapy Department, E.O. Galliera Hospital, Mura delle Cappuccine 14, 16128 Genoa, Italy
4Nuclear Medicine Department, Azienda Sanitaria dell’Alto Adige, Via Lorenz Böhler 5, 39100 Bolzano, Italy

Received 12 February 2014; Accepted 10 April 2014; Published 30 April 2014

Academic Editor: Riccardo Schiavina

Copyright © 2014 Arnoldo Piccardo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. B. Chism, A. L. Hanlon, E. M. Horwitz, S. J. Feigenberg, and A. Pollack, “A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy,” International Journal of Radiation Oncology, Biology, Physics, vol. 59, no. 2, pp. 380–385, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Roach III, G. Hanks, H. Thames Jr. et al., “Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference,” International Journal of Radiation Oncology, Biology, Physics, vol. 65, no. 4, pp. 965–974, 2006. View at Publisher · View at Google Scholar
  3. S. F. Slovin, A. S. Wilton, G. Heller, and H. I. Scher, “Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy,” Clinical Cancer Research, vol. 11, no. 24, pp. 8669–8673, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. R. A. Older, M. C. Lippert, S. B. Gay, R. A. Omary, and B. J. Hillman, “Computed tomography appearance of the prostatic fossa following radical prostatectomy,” Academic Radiology, vol. 2, no. 6, pp. 472–474, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. A. K. Leventis, S. F. Shariat, and K. M. Slawin, “Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings,” Radiology, vol. 219, no. 2, pp. 432–439, 2001. View at Google Scholar · View at Scopus
  6. E. Even-Sapir, U. Metser, E. Mishani, G. Lievshitz, H. Lerman, and I. Leibovitch, “The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F- Fluoride PET/CT,” The Journal of Nuclear Medicine, vol. 47, no. 2, pp. 287–297, 2006. View at Google Scholar · View at Scopus
  7. L. M. Wu, J. R. Xu, H. Y. Gu et al., “Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy,” Clinical Oncology, vol. 25, no. 4, pp. 252–264, 2013. View at Publisher · View at Google Scholar
  8. M. Cimitan, R. Bortolus, S. Morassut et al., “[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 12, pp. 1387–1398, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. D. B. Husarik, R. Miralbell, M. Dubs et al., “Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 2, pp. 253–263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Ceci, P. Castellucci, T. Graziani et al., “11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 5, pp. 878–886, 2014. View at Publisher · View at Google Scholar
  11. A. Wetter, C. Lipponer, F. Nensa et al., “Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results,” Investigative Radiology, vol. 48, no. 5, pp. 256–262, 2013. View at Publisher · View at Google Scholar
  12. A. Wetter, C. Lipponer, F. Nensa et al., “Evaluation of the PET component of simultaneous [18F]choline PET/MRI in prostate cancer: comparison with [18F]choline PET/CT,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 1, pp. 79–88, 2014. View at Publisher · View at Google Scholar
  13. A. J. Beer, M. Eiber, M. Souvatzoglou et al., “Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in 11C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer,” Molecular Imaging and Biology, vol. 13, no. 2, pp. 352–361, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Heidenreich, J. Bellmunt, M. Bolla et al., “EAU guidelines on prostate cancer—part 1: screening, diagnosis, and treatment of clinically localised disease,” European Urology, vol. 59, no. 1, pp. 61–71, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J. O. Barentsz, J. Richenberg, R. Clements et al., “ESUR prostate MR guidelines 2012,” European Radiology, vol. 22, no. 4, pp. 746–757, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Chondrogiannis, M. C. Marzola, A. Ferretti et al., “Role of 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 9, pp. 1356–1364, 2013. View at Publisher · View at Google Scholar
  17. H. Park, D. Wood, H. Hussain et al., “Introducing parametric fusion PET/MRI of primary prostate cancer,” The Journal of Nuclear Medicine, vol. 53, no. 4, pp. 546–551, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Beheshti, R. Vali, P. Waldenberger et al., “Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 10, pp. 1766–1774, 2008. View at Publisher · View at Google Scholar · View at Scopus